文献速递心律失常冠心病

房颤合并PCI患者最佳抗血栓方案:更新网状荟萃分析

Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis.
PubMed 文献 · JAMA Cardiol · 2020-01-01

结果显示,与VKA联合DAPT相比,NOAC联合P2Y12抑制剂不伴阿司匹林可显著降低TIMI大出血风险(OR 0.52,95%CI 0.35-0.79),且MACE无差异(OR 1.03,95%CI 0.77-1.38)。结论提示应避免VKA联合DAPT,NOAC联合P2Y12抑制剂可能是首选方案。

要点

  • 与VKA联合DAPT相比,NOAC联合P2Y12抑制剂显著降低TIMI大出血风险。
  • 所有含阿司匹林停用的方案在MACE上均与VKA联合DAPT无显著差异。
  • NOAC联合P2Y12抑制剂可能是房颤合并PCI患者首选抗血栓方案。

核心结论

  • 应避免VKA联合DAPT,因停用阿司匹林的方案出血风险更低且抗栓疗效无差异。
  • NOAC联合P2Y12抑制剂不伴阿司匹林可能是多数房颤合并PCI患者最有利的首选方案。

研究设计与样本

  • 采用贝叶斯随机效应模型,遵循PRISMA指南,数据检索自MEDLINE,分析时间为2019年9月9日至29日。

主要发现

  • 与VKA联合DAPT相比,TIMI大出血的OR(95%可信区间)为:VKA联合P2Y12抑制剂0.57(0.31-1.00),NOAC联合DAPT 0.69(0.40-1.16),NOAC联合P2Y12抑制剂0.52(0.35-0.79)。
  • 与VKA联合DAPT相比,MACE的OR(95%可信区间)为:VKA联合P2Y12抑制剂0.97(0.64-1.42),NOAC联合DAPT 0.95(0.64-1.39),NOAC联合P2Y12抑制剂1.03(0.77-1.38)。
  • 参与者平均年龄70至72岁,男性占69%至83%,女性占20%至26%,白人占90%以上。

临床怎么用

  • 对于房颤合并PCI患者,优先考虑NOAC联合P2Y12抑制剂而不联用阿司匹林。
  • 避免常规使用VKA联合DAPT,以降低出血风险而不增加MACE。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Antithrombotic treatment in patients with atrial fibrillation (AF) and percutaneous coronary intervention (PCI) presents a balancing act with regard to bleeding and ischemic risks. OBJECTIVES: To evaluate the safety and efficacy of 4 antithrombotic regimens by conducting an up-to-date network meta-analysis and to identify the optimal treatment for patients with AF undergoing PCI. DATA SOURCES: Online computerized database (MEDLINE). STUDY SELECTION: Five randomized studies were included (N = 11 542; WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PCI). DATA EXTRACTION AND SYNTHESIS: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used in this network meta-analysis, in which bayesian random-effects models were applied. The data were analyzed from September 9 to 29, 2019. MAIN OUTCOMES AND MEASURES: The primary safety outcome was thrombolysis in myocardial infarction (TIMI) major bleeding and the primary efficacy outcome was trial-defined major adverse cardiovascular events (MACE). RESULTS: The total number of participants included in the study was 11 532. The mean age of the participants ranged from 70 to 72 years, 69% to 83% were male, 20% to 26% were female, and the participants were predominantly white (>90%). Compared with vitamin K antagonists (VKA) plus dual antiplatelet therapy (DAPT) (reference), the odds ratios (ORs) (95% credible intervals) for TIMI major bleeding were 0.57 (0.31-1.00) for VKA plus P2Y12 inhibitor, 0.69 (0.40-1.16) for non-VKA oral anticoagulant (NOAC) plus DAPT, and 0.52 (0.35-0.79) for NOAC plus P2Y12 inhibitor. For MACE, using VKA plus DAPT as reference, the ORs (95% credible intervals) were 0.97 (0.64-1.42) for VKA plus P2Y12 inhibitor, 0.95 (0.64-1.39) for NOAC plus DAPT, and 1.03 (0.77-1.38) for NOAC plus P2Y12 inhibitor. CONCLUSIONS AND RELEVANCE: The findings of this study suggest that an antithrombotic regimen of VKA plus DAPT should generally be avoided, because regimens in which aspirin is discontinued may lead to lower bleeding risk and no difference in antithrombotic effectiveness. The use of a NOAC plus a P2Y12 inhibitor without aspirin may be the most favorable treatment option and the preferred antithrombotic regimen for most patients with AF undergoing PCI.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Lopes RD, Hong H, Harskamp RE, et al. Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. JAMA Cardiol. 2020. PMID: 32101251. doi:10.1001/jamacardio.2019.6175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。